Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA8 | P11142 | 3/20 | 0.80 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.80 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | GAPDH | P04406 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | PNP | P00491 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HBB | P68871 | 1/20 | 0.56 |
| ▸ | FBP1 | P09467 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 2/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6434241 | 1.00 | HSPA8 (0.80) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL17412455 | 0.89 | HSPA8 (1.00) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL1145052 | 0.89 | HSPA8 (1.00) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL1145049 | 0.89 | HSPA8 (1.00) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL14779383 | 0.88 | HSPA8 (0.80) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL8494383 | 0.88 | HSPA5 (0.61) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL8494362 | 0.88 | HSPA5 (0.61) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL18952787 | 0.86 | ADK (0.65) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL18952790 | 0.86 | ADK (0.65) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL23498581 | 0.85 | HSPA8 (0.59) | HSPA8HSPA5RXFP1GAPDHHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264823-A1 | TREATMENT OF DISEASE | METASHAPE PHARMA AG (CH) | 2025-12-26 | — | — | WO | disclosed |
| US-20250127787-A1 | METHODS FOR TREATING PERIPHERAL NEUROPATHY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4408531-A1 | METHODS FOR TREATING PERIPHERAL NEUROPATHY | University of Pittsburgh - of the Commonwealth System of Higher Education (US) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023055531-A1 | METHODS FOR TREATING PERIPHERAL NEUROPATHY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230089949-A1 | SMALL MOLECULES FOR TREATING AGE-RELATED RETINAL DISEASES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-03-23 | — | — | US | disclosed |
| EP-4138820-A1 | SMALL MOLECULES FOR TREATING AGE-RELATED RETINAL DISEASES | University of Pittsburgh - of the Commonwealth System of Higher Education (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220054494-A1 | METHODS FOR TREATING BLADDER AND URETHRA DYSFUNCTION AND DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-02-24 | — | — | US | disclosed |
| WO-2021216461-A1 | SMALL MOLECULES FOR TREATING AGE-RELATED RETINAL DISEASES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2020186187-A1 | METHODS FOR TREATING BLADDER AND URETHRA DYSFUNCTION AND DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20050014164-A1 | Triplex-forming oligonucleotides containing modified purines and their applications | ERITJA RAMON (ES) | 2005-01-20 | — | — | US | disclosed |
| WO-2004037981-A2 | TRIPLEX-FORMING OLIGONUCLEOTIDES CONTAINING MODIFIED PURINES AND THEIR APPLICATIONS | CYGENE LABORATORIES, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089949-A1 | SMALL MOLECULES FOR TREATING AGE-RELATED RETINAL DISEASES | PNP, PDE6B, PDE6A | HSPA8 2353/4885HSPA5 4671/4885RXFP1 906/4885 |
| US-20250127787-A1 | METHODS FOR TREATING PERIPHERAL NEUROPATHY | PNP, PNPO, PRPH | HSPA8 2234/4885HSPA5 2317/4885RXFP1 4652/4885 |
| US-20220054494-A1 | METHODS FOR TREATING BLADDER AND URETHRA DYSFUNCTION AND DISEASE | PNP, UNG, PDE3A | HSPA8 1914/4885HSPA5 1861/4885RXFP1 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.